WASHINGTON (Reuters) - A U.S. Food and Drug Administration advisory panel recommended GlaxoSmithKline Plc's Votrient for treatment of advanced soft-tissue sarcoma, a relatively rare but aggressive ...
GlaxoSmithKline‘s (NYSE:GSK) kidney cancer drug Votrient now has U.S. Food and Drug Administration approval to treat another indication — advanced soft tissue sarcoma. Drug approval means that ...
Pazopanib tablets are indicated for the treatment of adults with advanced renal cell carcinoma and advanced soft tissue sarcoma who have received prior chemotherapy. Aurobindo’s wholly owned ...
WASHINGTON (Reuters) - GlaxoSmithKline's Votrient extended the lives of a significant number of patients suffering from an aggressive form of cancer without the disease getting worse, but the drug did ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results